Leuprorelin intranasal - Archimedes/West Pharmaceutical Services

Drug Profile

Leuprorelin intranasal - Archimedes/West Pharmaceutical Services

Alternative Names: leuprorelide intranasal - Archimedes

Latest Information Update: 31 Aug 2015

Price : $50

At a glance

  • Originator Archimedes Pharma; West Pharmaceutical Services
  • Developer Archimedes Pharma
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Endometriosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 30 Apr 2007 Phase-II clinical trials in Endometriosis in the US(Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top